Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4650492 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL3410926 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL4552520 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL21815627 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL21815659 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL11863747 | 0.91 | TSHR (0.43) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL7519407 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL9081703 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL3672952 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A | |
| SCHEMBL9856241 | 0.91 | MEN1 (0.33) | MEN1ALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | ASCENDIS PHARMA A/S (DK) | 2026-04-07 | — | — | US | disclosed |
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2021-11-04 | — | — | US | disclosed |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2021-10-28 | — | — | US | disclosed |
| EP-3856255-A1 | TREATMENT OF INFECTIONS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| EP-3856257-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | Ascendis Pharma A/S (DK) | 2021-08-04 | — | — | EP | disclosed |
| WO-2020064844-A1 | TREATMENT OF INFECTIONS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
| WO-2020064847-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | ASCENDIS PHARMA A/S (DK) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338834-A1 | DEGRADABLE HYALURONIC ACID HYDROGELS | CD44, HPSE, MMP13 | MEN1 2545/4885ALDH1A1 101/4885TSHR 1264/4885 |
| US-12594345-B2 | Degradable hyaluronic acid hydrogels | CD44, H1-0, MMP1 | MEN1 2382/4885ALDH1A1 210/4885TSHR 493/4885 |
| US-20210330798-A1 | TREATMENT OF INFECTIONS | H1-10, PM20D2, ELANE | MEN1 1654/4885ALDH1A1 1667/4885TSHR 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.